OBJECTIVE: To determine if levels of soluble intercellular adhesion molecule-1 (sICAM-1), a marker of alveolar epithelial and endothelial injury, differ in patients with hydrostatic pulmonary edema and acute lung injury (ALI) and are associated with clinical outcomes in patients with ALI. DESIGN, SETTING, AND PARTICIPANTS: Measurement of sICAM-1 levels in (1) plasma and edema fluid from 67 patients with either hydrostatic pulmonary edema or ALI enrolled in an observational, prospective single center study, and (2) in plasma from 778 patients with ALI enrolled in a large multi-center randomized controlled trial of ventilator strategy. RESULTS: In the single-center study, levels of sICAM-1 were significantly higher in both edema fluid and plasma (median 938 and 545 ng/ml, respectively) from ALI patients compared to hydrostatic edema patients (median 384 and 177 ng/ml, P < 0.03 for both comparisons). In the multi-center study, higher plasma sICAM-1 levels were associated with poor clinical outcomes in both unadjusted and multivariable models. Subjects with ALI whose plasma sICAM-1 levels increased over the first 3 days of the study had a higher risk of death, after adjusting for other important predictors of outcome (odds ratio 1.48; 95% CI 1.03-2.12, P = 0.03). CONCLUSIONS: Both plasma and edema fluid levels of sICAM-1 are higher in patients with ALI than in patients with hydrostatic pulmonary edema. Higher plasma sICAM-1 levels and increasing sICAM-1 levels over time are associated with poor clinical outcomes in ALI. Measurement of sICAM-1 levels may be useful for identifying patients at highest risk of poor outcomes from ALI.
RCT Entities:
OBJECTIVE: To determine if levels of soluble intercellular adhesion molecule-1 (sICAM-1), a marker of alveolar epithelial and endothelial injury, differ in patients with hydrostatic pulmonary edema and acute lung injury (ALI) and are associated with clinical outcomes in patients with ALI. DESIGN, SETTING, AND PARTICIPANTS: Measurement of sICAM-1 levels in (1) plasma and edema fluid from 67 patients with either hydrostatic pulmonary edema or ALI enrolled in an observational, prospective single center study, and (2) in plasma from 778 patients with ALI enrolled in a large multi-center randomized controlled trial of ventilator strategy. RESULTS: In the single-center study, levels of sICAM-1 were significantly higher in both edema fluid and plasma (median 938 and 545 ng/ml, respectively) from ALI patients compared to hydrostatic edemapatients (median 384 and 177 ng/ml, P < 0.03 for both comparisons). In the multi-center study, higher plasma sICAM-1 levels were associated with poor clinical outcomes in both unadjusted and multivariable models. Subjects with ALI whose plasma sICAM-1 levels increased over the first 3 days of the study had a higher risk of death, after adjusting for other important predictors of outcome (odds ratio 1.48; 95% CI 1.03-2.12, P = 0.03). CONCLUSIONS: Both plasma and edema fluid levels of sICAM-1 are higher in patients with ALI than in patients with hydrostatic pulmonary edema. Higher plasma sICAM-1 levels and increasing sICAM-1 levels over time are associated with poor clinical outcomes in ALI. Measurement of sICAM-1 levels may be useful for identifying patients at highest risk of poor outcomes from ALI.
Authors: G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher Journal: N Engl J Med Date: 2001-03-08 Impact factor: 91.245
Authors: M D Eisner; T Thompson; L D Hudson; J M Luce; D Hayden; D Schoenfeld; M A Matthay Journal: Am J Respir Crit Care Med Date: 2001-07-15 Impact factor: 21.405
Authors: C Madjdpour; B Oertli; U Ziegler; J M Bonvini; T Pasch; B Beck-Schimmer Journal: Am J Physiol Lung Cell Mol Physiol Date: 2000-03 Impact factor: 5.464
Authors: M Covarrubias; L B Ware; S M Kawut; J De Andrade; A Milstone; A Weinacker; J Orens; V Lama; K Wille; S Bellamy; C Shah; E Demissie; J D Christie Journal: Am J Transplant Date: 2007-10-01 Impact factor: 8.086
Authors: Mark E Mikkelsen; Chirag V Shah; Arnaud Scherpereel; Paul N Lanken; Philippe Lassalle; Scarlett L Bellamy; A Russell Localio; Steven M Albelda; Nuala J Meyer; Jason D Christie Journal: J Crit Care Date: 2011-09-29 Impact factor: 3.425
Authors: Carolyn S Calfee; Lorraine B Ware; David V Glidden; Mark D Eisner; Polly E Parsons; B Taylor Thompson; Michael A Matthay Journal: Crit Care Med Date: 2011-04 Impact factor: 7.598
Authors: John P Reilly; Nuala J Meyer; Michael G S Shashaty; Rui Feng; Paul N Lanken; Robert Gallop; Sandra Kaplan; Maximilian Herlim; Nathaniel L Oz; Isabel Hiciano; Ana Campbell; Daniel N Holena; Muredach P Reilly; Jason D Christie Journal: Chest Date: 2014-04 Impact factor: 9.410
Authors: Carolyn S Calfee; Kevin Delucchi; Polly E Parsons; B Taylor Thompson; Lorraine B Ware; Michael A Matthay Journal: Lancet Respir Med Date: 2014-05-19 Impact factor: 30.700
Authors: John P Reilly; Nuala J Meyer; Michael Gs Shashaty; Brian J Anderson; Caroline Ittner; Thomas G Dunn; Brian Lim; Caitlin Forker; Michael P Bonk; Ethan Kotloff; Rui Feng; Edward Cantu; Nilam S Mangalmurti; Carolyn S Calfee; Michael A Matthay; Carmen Mikacenic; Keith R Walley; James Russell; David C Christiani; Mark M Wurfel; Paul N Lanken; Muredach P Reilly; Jason D Christie Journal: J Clin Invest Date: 2021-01-04 Impact factor: 14.808